OBJECTIVE: S100B is viewed as the most promising biomarker for brain damage. It has been proposed that this marker is useful in a Neurointensive Care Unit (NICU) as a monitoring parameter. This study aims to examine the clinical usefulness of daily serum S100B measurements in this setting. DESIGN: Prospective consecutive inclusion of patients. PATIENTS: A total of 79 patients with confirmed or suspected head injury or cerebrovascular insults (CVIs) (based upon patient history, computed tomography (CT) and/or magnetic resonance imaging (MRI) and neurological examination including coma scoring) who required neurointensive care were included in the study. INTERVENTIONS: Sampling for S100B was performed at admission and daily until patients were discharged from the NICU. S100B measurements were statistically compared to occurrence of secondary complications and outcome according to Glasgow Outcome Scale (GOS), with focus on clinical prediction. MEASUREMENTS AND MAIN RESULTS: 17 of 79 patients (22%) had secondary neurological complications. Mean S100B levels were found to be an independent parameter associated with these complications (P=0.03). Mean S100B levels were higher in patients with complications compared to those without on both the complication day (P=0.033) and the day after (P=0.015), but not the day prior to the complication (P=0.62). S100B did not predict secondary neurological complication. Neither mean (P=0.182) nor peak (P=0.370) S100B levels were associated with or predicted outcome according to dichotomised GOS. CONCLUSION: Daily S100B measurements are associated with secondary complications but not to outcome. However, daily S100B levels do not predict secondary complications, which limit the usefulness of this brain biomarker in this setting.
OBJECTIVE: S100B is viewed as the most promising biomarker for brain damage. It has been proposed that this marker is useful in a Neurointensive Care Unit (NICU) as a monitoring parameter. This study aims to examine the clinical usefulness of daily serum S100B measurements in this setting. DESIGN: Prospective consecutive inclusion of patients. PATIENTS: A total of 79 patients with confirmed or suspected head injury or cerebrovascular insults (CVIs) (based upon patient history, computed tomography (CT) and/or magnetic resonance imaging (MRI) and neurological examination including coma scoring) who required neurointensive care were included in the study. INTERVENTIONS: Sampling for S100B was performed at admission and daily until patients were discharged from the NICU. S100B measurements were statistically compared to occurrence of secondary complications and outcome according to Glasgow Outcome Scale (GOS), with focus on clinical prediction. MEASUREMENTS AND MAIN RESULTS: 17 of 79 patients (22%) had secondary neurological complications. Mean S100B levels were found to be an independent parameter associated with these complications (P=0.03). Mean S100B levels were higher in patients with complications compared to those without on both the complication day (P=0.033) and the day after (P=0.015), but not the day prior to the complication (P=0.62). S100B did not predict secondary neurological complication. Neither mean (P=0.182) nor peak (P=0.370) S100B levels were associated with or predicted outcome according to dichotomised GOS. CONCLUSION: Daily S100B measurements are associated with secondary complications but not to outcome. However, daily S100B levels do not predict secondary complications, which limit the usefulness of this brain biomarker in this setting.
Authors: Andreas Raabe; Olaf Kopetsch; Alina Woszczyk; Josef Lang; Rüdiger Gerlach; Michael Zimmermann; Volker Seifert Journal: Neurol Res Date: 2004-06 Impact factor: 2.448
Authors: Eric S Weiss; Kevin K W Wang; Jeremiah G Allen; Mary E Blue; Lois U Nwakanma; Ming Cheng Liu; Mary S Lange; Jennifer Berrong; Mary Ann Wilson; Vincent L Gott; Juan C Troncoso; Ronald L Hayes; Michael V Johnston; William A Baumgartner Journal: Ann Thorac Surg Date: 2009-08 Impact factor: 4.330
Authors: Ericka L Fink; Rachel P Berger; Robert S B Clark; Robert S Watson; Derek C Angus; Rudolph Richichi; Ashok Panigrahy; Clifton W Callaway; Michael J Bell; Patrick M Kochanek Journal: Crit Care Med Date: 2014-03 Impact factor: 7.598
Authors: Jan Florian Heuer; Paolo Pelosi; Peter Hermann; Christina Perske; Thomas A Crozier; Wolfgang Brück; Michael Quintel Journal: Intensive Care Med Date: 2011-05-05 Impact factor: 17.440
Authors: Eric Peter Thelin; Frederick Adam Zeiler; Ari Ercole; Stefania Mondello; András Büki; Bo-Michael Bellander; Adel Helmy; David K Menon; David W Nelson Journal: Front Neurol Date: 2017-07-03 Impact factor: 4.003